Below you will find information from the register publication of inside information. The information has been provided by the organisation.
- Registration date 29 aug 2018 - 07:00
- Statutory name argenx SE
- Title argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis
|201808290000000004_argenx receives feedback from Japan.docx|
Date last update: 16 January 2021